Atea Pharmaceuticals Inc

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

AVIR$4.20-4.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

(in thousands)

	Nine Months EndedSeptember 30,
	2024	2023
Cash flows from operating activities
Net loss	$(134,842)	$(96,792)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	37,470	37,271
Depreciation and amortization expense	312	312
Accretion of premium and discounts on marketable securities	(9,108)	(11,101)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	8,256	6,023
Other assets	(287)	98
Accounts payable	1,533	(2,156)
Accrued expenses and other liabilities	(8,306)	2,904
Operating lease liabilities	(130)	(120)
Net cash used in operating activities	(105,102)	(63,561)
Cash flows from investing activities
Purchases of marketable securities	(402,702)	(515,132)
Sales and maturities of marketable securities	462,177	527,664
Net cash provided by investing activities	59,475	12,532
Cash flows from financing activities
Proceeds from issuance of common stock under ESPP	267	257
Net cash provided by financing activities	267	257
Net decrease in cash and cash equivalents	(45,360)	(50,772)
Cash and cash equivalents at the beginning of period	143,823	188,658
Cash and cash equivalents at the end of period	$98,463	$137,886

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.